Illumina Inc (ILMN.O) News| Reuters.com
Edition:
United States

Illumina Inc (ILMN.O)

ILMN.O on Nasdaq

137.58USD
29 Jun 2016
Change (% chg)

-- (--)
Prev Close
$137.58
Open
--
Day's High
--
Day's Low
--
Volume
201
Avg. Vol
1,366,744
52-wk High
$242.37
52-wk Low
$127.10

Select another date:

Wed, Jun 29 2016

BRIEF-Natera and Illumina extend supply agreement, broaden existing partnership to include oncology field

* Natera and Illumina extend supply agreement, broaden existing partnership to include oncology field Source text for Eikon: Further company coverage: )

BRIEF-Natera, Illumina Inc enter 3rd amendment to supply agreement dated August 16, 2013

* On June 8, 2016, co and Illumina Inc entered into third amendment to a supply agreement dated August 16, 2013

Illumina claims Cornell obtained gene-sequencing patent unfairly

A federal magistrate judge has recommended that biotechnology company Illumina Inc be allowed to file claims accusing Cornell University employees of deceiving the U.S. Patent and Trademark Office in order to obtain a gene-sequencing patent it now accuses Illumina of infringing.

Federal Circuit upholds Illumina gene-sequencing patent

A federal appeals court has upheld gene-sequencing company Illumina Inc's patent on a method of labeling nucleotides, the individual building blocks of DNA, rejecting a challenge by a unit of rival Quiagen NV.

BRIEF-Illumina received a product approval certificate for MiSeqDx instrument

* Received a product approval certificate for Miseqdx Instrument and Miseqdx universal kit with MFDS in South Korea Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

BRIEF-Illumina Q1 non-GAAP earnings per share $0.71

* Illumina reports financial results for first quarter of fiscal year 2016

BRIEF-Illumina have filed a patent infringement suit against Esperite subsidiary Genoma

* Illumina and its subsidiary Verinata Health, have filed a patent infringement suit against subsidiary Genoma in federal patent court in Switzerland

BRIEF-Illumina files patent infringement suit against Genoma SA

* Illumina files patent infringement suit in Switzerland against Genoma SA for infringement of NIPT patents

CORRECTED-BRIEF-Illumina committed to invest $100 million in new venture capital firm

* Committed to invest $100 million in a new venture capital firm

BRIEF-Illumina says CEO Jay Flatley's 2015 compensation was $9.2 mln vs $14.9 mln in 2014

* CEO Jay T. Flatley 2015 total compensation of $9.2 million versus $14.9 million in 2014 - SEC filing Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

Select another date: